Copyright: ©Author(s) 2026.
World J Gastroenterol. May 7, 2026; 32(17): 117823
Published online May 7, 2026. doi: 10.3748/wjg.v32.i17.117823
Published online May 7, 2026. doi: 10.3748/wjg.v32.i17.117823
Table 2 Tumor and inflammatory biomarkers of gastric cancer undergoing immunotherapy
| Characteristics | Death (n = 157) | Survival (n = 73) | χ2/U value | P value |
| CEA (ng/mL), median (IQR) | 37.54 (29.27, 41.25) | 32.89 (23.95, 38.66) | 4447 | 0.006 |
| CA199 (U/mL), median (IQR) | 44.15 (36.75, 53.46) | 35.16 (26.45, 43.22) | 3316 | < 0.001 |
| NLR, median (IQR) | 7.05 (5.30, 9.33) | 6.37 (5.23, 8.47) | 4735 | 0.034 |
| PLR, median (IQR) | 207.10 (108.90, 315.00) | 198.70 (133.80, 347.80) | 5372 | 0.447 |
| PIV, median (IQR) | 1286 (955.1, 1416) | 1239 (1142, 1352) | 5403 | 0.487 |
| SII, median (IQR) | 1452 (752.5, 2318) | 1246 (989.4, 1859) | 5654 | 0.871 |
- Citation: Zheng PM, Ouyang LB, Wang R, Jing KY, Gao HJ, Zhu CK. Clinical significance of autoantibody profiling and systemic inflammation in predicting outcomes of gastric cancer patients undergoing immunotherapy. World J Gastroenterol 2026; 32(17): 117823
- URL: https://www.wjgnet.com/1007-9327/full/v32/i17/117823.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i17.117823